|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Igm Biosciences, Inc. (IGMS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
24,220,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Co.'s primary product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. Co.'s second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 proteins. Co.'s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell targeting CD38 and CD3 proteins and IGM-2537, a bispecific T cell targeting CD123, and CD3 proteins.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
395,317 |
928,010 |
1,130,933 |
1,227,818 |
Total Buy Value |
$3,425,569 |
$6,857,033 |
$8,606,797 |
$10,246,311 |
Total People Bought |
1 |
1 |
5 |
6 |
Total Buy Transactions |
3 |
6 |
11 |
20 |
Total Shares Sold |
28,125 |
64,791 |
154,362 |
286,636 |
Total Sell Value |
$281,621 |
$492,429 |
$1,355,835 |
$4,051,715 |
Total People Sold |
6 |
7 |
8 |
8 |
Total Sell Transactions |
12 |
21 |
30 |
62 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Topsoe Christina Teng |
Director |
|
2022-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
346 |
37,275 |
|
- |
|
Loberg Michael D |
Director |
|
2022-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
533 |
533 |
|
- |
|
Behrens M Kathleen |
Director |
|
2022-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
374 |
3,020 |
|
- |
|
Green Jeremy |
Director |
|
2022-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
230 |
3,336,047 |
|
- |
|
Tahir Misbah |
Chief Financial Officer |
|
2022-05-26 |
4 |
S |
$17.10 |
$16,247 |
D/D |
(950) |
33,698 |
|
- |
|
Gauthier George |
Chief Commercial Officer |
|
2022-05-24 |
4 |
S |
$17.10 |
$22,917 |
D/D |
(1,340) |
25,236 |
|
- |
|
Takimoto Chris H |
Chief Medical Officer |
|
2022-05-24 |
4 |
S |
$17.10 |
$16,043 |
D/D |
(938) |
36,864 |
|
- |
|
Decker Lisa Lynn |
Chief Business Officer |
|
2022-05-24 |
4 |
S |
$17.10 |
$23,293 |
D/D |
(1,362) |
21,535 |
|
- |
|
Keyt Bruce |
Chief Scientific Officer |
|
2022-05-24 |
4 |
S |
$17.10 |
$16,058 |
D/D |
(939) |
39,489 |
|
- |
|
Schwarzer Fred |
CEO and President |
|
2022-05-24 |
4 |
S |
$17.10 |
$23,294 |
D/D |
(1,362) |
33,987 |
|
- |
|
Topsoe Jakob Haldor |
Director |
|
2022-05-20 |
4 |
B |
$16.00 |
$23,696 |
D/D |
1,481 |
73,462 |
3.92 |
- |
|
Topsoe Christina Teng |
Director |
|
2022-05-13 |
4 |
B |
$14.99 |
$67,593 |
I/I |
4,510 |
6,800 |
2.25 |
- |
|
Topsoe Jakob Haldor |
Director |
|
2022-05-13 |
4 |
B |
$14.86 |
$116,683 |
D/D |
7,850 |
71,981 |
3.92 |
- |
|
Schwarzer Fred |
CEO and President |
|
2022-05-13 |
4 |
A |
$12.38 |
$5,125 |
D/D |
414 |
35,349 |
|
- |
|
Takimoto Chris H |
Chief Medical Officer |
|
2022-05-13 |
4 |
A |
$12.38 |
$10,214 |
D/D |
825 |
37,802 |
|
- |
|
Tahir Misbah |
Chief Financial Officer |
|
2022-05-13 |
4 |
A |
$12.38 |
$4,841 |
D/D |
391 |
34,648 |
|
- |
|
Keyt Bruce |
Chief Scientific Officer |
|
2022-05-13 |
4 |
A |
$12.38 |
$5,113 |
D/D |
413 |
40,428 |
|
- |
|
Gauthier George |
Chief Commercial Officer |
|
2022-05-13 |
4 |
A |
$12.38 |
$5,113 |
D/D |
413 |
26,576 |
|
- |
|
Decker Lisa Lynn |
Chief Business Officer |
|
2022-05-13 |
4 |
A |
$12.38 |
$5,113 |
D/D |
413 |
22,897 |
|
- |
|
Topsoe Christina Teng |
Director |
|
2022-05-12 |
4 |
B |
$14.08 |
$32,248 |
I/I |
2,290 |
2,290 |
2.25 |
- |
|
Topsoe Jakob Haldor |
Director |
|
2022-05-12 |
4 |
B |
$14.17 |
$116,991 |
D/D |
8,254 |
64,131 |
3.92 |
- |
|
Loberg Michael D |
Director |
|
2022-04-08 |
4 |
GA |
$0.00 |
$0 |
I/I |
533 |
22,272 |
|
- |
|
Loberg Michael D |
Director |
|
2022-04-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
533 |
0 |
|
- |
|
Keyt Bruce |
Chief Scientific Officer |
|
2022-04-06 |
4 |
AS |
$25.00 |
$62,500 |
D/D |
(2,500) |
40,015 |
|
- |
|
Keyt Bruce |
Chief Scientific Officer |
|
2022-04-06 |
4 |
OE |
$0.93 |
$2,325 |
D/D |
2,500 |
42,515 |
|
- |
|
222 Records found
|
|
Page 2 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|